Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
about
Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological AbnormalitiesMinor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.Perceived effectiveness of HPV test as a primary screening modality among US providers.Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New ZealandReceiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR.Management of high-risk HPV-positive women for detection of cervical (pre)cancer.Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions.Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial.Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions.Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trialLong-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial.Carcinogenic human papillomavirus infection.Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.Primary HPV testing recommendations of US providers, 2015.Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.HPV prophylactic vaccines: lessons learned from 10 years experienceCervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China
P2860
Q35203306-41BB3800-B95C-4431-BA3C-6C1B6EAEEE16Q35498040-C7D494B3-7810-4F2E-9359-87745DB00193Q35665790-AA7B9A5E-FD3A-4623-BF9B-EF31EB0B6350Q35870574-227F288C-4917-4730-B423-58DB1FFDCB83Q35991566-60C26ECD-A576-42E2-851B-C4F026B03D87Q36019886-FF0E229D-0A11-4736-A1F9-2EC568738659Q36303181-13C6A517-F77E-47C9-9499-3A2057E83986Q37132091-941CA96E-4336-465F-9476-D9FBAC896BAFQ38837737-9348910C-979C-47AE-AF83-84C7DA3171AEQ39177983-AE9D28DD-9F78-4140-8C5E-A86C81B686CCQ39189708-0D9874E6-528C-4958-83F2-60C881E158DCQ39477130-54868B88-93EF-406B-936C-8F153104E25EQ40142951-5893EC94-E69D-40A3-AFD3-70B19CFD417EQ41611517-63FF2C22-1EB0-4AA8-9D2E-4C7D5D3A6DD0Q41612137-C89B8DAC-E6DA-4E47-88BC-09515F96EC47Q41677108-3B16302D-7868-495A-8795-4EC9D713257CQ42204957-73020D25-C615-4462-A624-6DA3A54AC19EQ44863515-C14EEAE2-09C0-4A00-AE57-05C69FD7FE02Q47106806-76A8F2E4-5428-45CD-A672-C023D365FC49Q47747921-7C578C37-9EBC-4176-ABA4-2C7C2EED743CQ49644195-D8789B44-6058-49E6-88BD-AD5C66F181CEQ50000948-F84C5E37-D948-4BBC-99E5-30C883DE9A07Q56067928-BBA45A95-07A1-4894-B0E2-2D4F3CA0D373Q58764889-BBB351EA-9907-4EDD-88B4-C1525F9B1F9D
P2860
Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long term duration of protecti ...... g randomised controlled trial.
@en
Long term duration of protecti ...... g randomised controlled trial.
@nl
type
label
Long term duration of protecti ...... g randomised controlled trial.
@en
Long term duration of protecti ...... g randomised controlled trial.
@nl
prefLabel
Long term duration of protecti ...... g randomised controlled trial.
@en
Long term duration of protecti ...... g randomised controlled trial.
@nl
P2093
P2860
P50
P356
P1433
P1476
Long term duration of protecti ...... ng randomised controlled trial
@en
P2093
Carina Eklund
Joakim Dillner
K Miriam Elfström
Pontus Nauclér
P2860
P356
10.1136/BMJ.G130
P407
P577
2014-01-16T00:00:00Z